We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




PCR Assay Detects and Differentiates Coccidioides Species

By LabMedica International staff writers
Posted on 07 Oct 2021
Print article
Image: The QIAcube is an automated system which can extract DNA or RNA from up to 12 samples simultaneously (Photo courtesy of Qiagen)
Image: The QIAcube is an automated system which can extract DNA or RNA from up to 12 samples simultaneously (Photo courtesy of Qiagen)
Coccidioidomycosis (Valley Fever) is a pulmonary and systemic fungal disease with increasing incidence and expanding endemic areas. The differentiation of etiologic agents Coccidioides immitis and C. posadasii remains problematic in the clinical laboratories as conventional PCR and satellite typing schemes are difficult.

Notable coccidioidomycosis signs and symptoms include a profound feeling of tiredness, loss of smell and taste, fever, cough, headaches, rash, muscle pain, and joint pain. Fatigue can persist for many months after initial infection. The classic triad of coccidioidomycosis known as "desert rheumatism" includes the combination of fever, joint pains, and erythema nodosum.

Mycologists at the Wadsworth Center (New York, NY, USA) and their colleagues analyzed 217 suspected isolates of Coccidioides species, 10 formalin-fixed paraffin-embedded tissues, three vials of rhesus monkey kidney, six lung tissue samples, three cerebrospinal fluids (CSF), two bone marrows, one plural fluid, and one whole blood sample. Seventeen isolates of C. immitis and 15 CSF and pleural fluids, which tested positive for coccidioidomycosis by immunodiffusion and complement fixation, were also included in the study.

The scientists used the Qiagen DNA mini kit on the QIAcube automated extractor (Qiagen, Venlo, The Netherlands) for DNA extraction from all sample types. A modification of conventional diagnostic PCR was used. The PRA2 gene and contig Ci41815/Cp45809 were used to design the duplex real-time PCR assay. The assay specificity was assessed by using an extensive DNA panel comprising various fungi both closely and distantly related to Coccidioides spp. and few bacterial pathogens primarily responsible for causing pulmonary infection. The team developed Cy5- and FAM-labeled TaqMan-probes for duplex real-time PCR assay for rapid differentiation of C. immitis and C. posadasii from culture and clinical specimens.

The investigators reported that the assay was highly sensitive with limit of detection of 0.1 pg gDNA/PCR reaction, which was equivalent to approximately ten genome copies of C. immitis or C. posadasii. The assay was highly specific with no cross-reactivity to the wide range of fungal and bacterial pathogens. Retrospective analysis of fungal isolates and primary specimens submitted from 1995 to 2020 confirmed 168 isolates and four primary specimens as C. posadasii and 30 isolates as C. immitis from human coccidioidomycosis cases, while all eight primary samples from two animals (rhesus monkey and rhinoceros) were confirmed as C. posadasii. A preliminary analysis of cerebrospinal fluid (CSF) and pleural fluid samples showed positive correlation between serology tests and real-time PCR for two of the 15 samples.

The authors concluded that their modified diagnostic conventional PCR assay was excellent for the culture identification of C. immitis and C. posadasii, and the new duplex real-time PCR assay had broader utility for identifying two Coccidioides species from culture and primary specimens. The Coccidioides spp. duplex real-time PCR will allow rapid differentiation of C. immitis and C. posadasii from clinical specimens and further augment coccidioidomycosis treatment and surveillance. The study was published on September 16, 2021 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Wadsworth Center
Qiagen


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
High Performance Centrifuge
CO336/336R
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.